Canada Markets close in 1 hr 26 mins

PharmaTher Holdings Ltd. (PHRRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1000+0.0032 (+3.31%)
As of 12:25PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.0968
Open0.0902
BidN/A x N/A
AskN/A x N/A
Day's Range0.0902 - 0.1000
52 Week Range0.0370 - 0.2750
Volume147,336
Avg. Volume134,136
Market Cap6.904M
Beta (5Y Monthly)N/A
PE Ratio (TTM)3.23
EPS (TTM)0.0310
Earnings DateOct 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

    TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from

  • GlobeNewswire

    PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

    Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA approvals for KETARX™ via the ANDA and 505(b)(2) regulatory pathways in H2-2023 Company aims to advance clinical development programs of KETARX™, including (i) Phase 3 clinical study for Parkinson’s disease; (ii) Phase 2 clinical study with microneedle patch; and (iii) Phase 2 clinical study for Amyotrophic lateral sclerosis Company granted 4 FDA orpha

  • GlobeNewswire

    PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

    PharmaTher’s 4th FDA orphan drug designation for ketamineTORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation. The Company currently holds four orphan drug designations granted by the FDA